Effect of donor pretreatment with peg-G-CSF on GVHD histopathology
. | Day 8 after treatment . | . | . | . | Day 10 to 12 after treatment . | . | . | Day 60 after treatment . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | Control syngeneic . | Control allogeneic . | G-CSF allogeneic . | Peg-G-CSF allogeneic . | Control allogeneic . | G-CSF allogeneic . | Peg-G-CSF allogeneic . | Control syngeneic . | Peg-G-CSF allogeneic . | ||||||
| Cutaneous GVHD | 1.0 ± 0.2 | 10.1 ± 1.1 | 10.5 ± 1.2 | 13.0 ± 1.3 | 11.4 ± 0.7 | 12.3 ± 0.7 | 15.1 ± 0.6 | 0.5 ± 0.5 | 0.3 ± 0.1 | ||||||
| GI tract GVHD | 2.3 ± 0.3 | 14.7 ± 1.9 | 14.1 ± 2.9 | 13.8 ± 0.4 | 24.0 ± 1.3 | 18.5 ± 4.6 | 4.7 ± 0.3 | 0.3 ± 0.3 | 1.4 ± 0.6 | ||||||
| Hepatic GVHD | 0.6 ± 0.2 | 5.0 ± 0.8 | 3.3 ± 0.7 | 11.2 ± 1.3 | 6.3 ± 0.5 | 19.2 ± 0.9 | 12.7 ± 0.9 | 1.8 ± 0.3 | 8.6 ± 1.6 | ||||||
. | Day 8 after treatment . | . | . | . | Day 10 to 12 after treatment . | . | . | Day 60 after treatment . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | Control syngeneic . | Control allogeneic . | G-CSF allogeneic . | Peg-G-CSF allogeneic . | Control allogeneic . | G-CSF allogeneic . | Peg-G-CSF allogeneic . | Control syngeneic . | Peg-G-CSF allogeneic . | ||||||
| Cutaneous GVHD | 1.0 ± 0.2 | 10.1 ± 1.1 | 10.5 ± 1.2 | 13.0 ± 1.3 | 11.4 ± 0.7 | 12.3 ± 0.7 | 15.1 ± 0.6 | 0.5 ± 0.5 | 0.3 ± 0.1 | ||||||
| GI tract GVHD | 2.3 ± 0.3 | 14.7 ± 1.9 | 14.1 ± 2.9 | 13.8 ± 0.4 | 24.0 ± 1.3 | 18.5 ± 4.6 | 4.7 ± 0.3 | 0.3 ± 0.3 | 1.4 ± 0.6 | ||||||
| Hepatic GVHD | 0.6 ± 0.2 | 5.0 ± 0.8 | 3.3 ± 0.7 | 11.2 ± 1.3 | 6.3 ± 0.5 | 19.2 ± 0.9 | 12.7 ± 0.9 | 1.8 ± 0.3 | 8.6 ± 1.6 | ||||||
Recipients received transplants as described in “Materials and methods.” Tissue was collected from control allogeneic animals (n = 11), G-CSF allogeneic animals (n = 6), peg-G- CSF allogeneic animals (n = 6), and control syngeneic animals (n = 4) at day 8 after treatment. Tissue was also collected from recipients on the day of maximal GVHD mortality (control pretreated donors [n = 6] at day 10 and from G-CSF pretreated at day 12 [n = 5]). Tissue was also collected from recipients of peg-G-CSF splenocytes at day 12 after transplantation as a comparison. The cutaneous, GI tract, and hepatic histopathology scores in syngeneic recipients at day 12 were 0.1 ± 0.1, 1.6 ± 0.2, and 2.4 ± 0.6, respectively. Finally, tissue was collected from syngeneic (n = 3) and peg-G-CSF allogeneic recipients (n = 5) at the termination of the experiment on day 60. Histopathology was scored as described in “Materials and methods.” Data presented as mean ± SEM. The scores at day 10 to 12 in control and G-CSF allogeneic recipients that are significantly higher than those in peg-G-CSF allogeneic recipients are shown in bold (P < .05). Histopathology scores in all allogeneic recipients were significantly higher than syngeneic recipients at days 8 and 10 to 12 (P < .05). At day 60, only the hepatic score in peg-G-CSF allogeneic recipients was significantly higher than that in syngeneic recipients (P < .05).